Clinical trial
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian…
NCT00003532 · Burzynski Research Institute, Other · Terminated
Key facts
| NCT number | NCT00003532 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Carcinoma of the Ovary |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage III Ovarian Cancer, Stage IV Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 7 |
| Start date | Mar 5, 1996 |
| Primary completion | Oct 18, 2002 |
| Completion | Oct 18, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: